Semax and Traumatic Brain Injury Research: Neuroprotection, Neuroinflammation and TBI Biology UK 2026

All content on this page is for research and educational purposes only. Semax is a research compound supplied for laboratory use. It is not approved for human therapeutic use in the UK and is not intended to diagnose, treat, cure or prevent any condition.

Introduction: TBI as a Research Priority

Traumatic brain injury (TBI) is a leading cause of death and long-term disability globally, affecting an estimated 50–60 million people annually. The spectrum ranges from mild concussive injuries (mTBI) with transient symptoms to severe TBI with prolonged unconsciousness, diffuse axonal injury, and permanent neurological deficit. Despite decades of research, no pharmacological agent has achieved robust efficacy in improving outcomes from moderate-to-severe TBI in well-powered clinical trials — a therapeutic gap that continues to drive intensive preclinical research activity.

Semax — a synthetic heptapeptide analogue of the ACTH4-7 sequence (Met-Glu-His-Phe-Pro-Gly-Pro) — has been investigated in TBI research models as a neuroprotective and neuroregenerative agent. Its established effects on BDNF expression, neuroinflammation modulation, and cerebral blood flow regulation make it mechanistically relevant to multiple components of the TBI injury cascade. This post examines what research models reveal about semax’s potential utility in TBI biology.

TBI Pathophysiology: Primary and Secondary Injury

TBI produces injury through two distinct but interacting phases:

Primary injury occurs at the moment of impact — direct mechanical disruption of neural tissue, axonal shearing (diffuse axonal injury, DAI), contusion, haemorrhage, and immediate cell death. Primary injury is determined by the force of impact and is not pharmacologically modifiable — no drug can prevent the initial mechanical damage.

Secondary injury begins within minutes of primary injury and continues for hours to weeks. It encompasses a cascade of pathophysiological processes that amplify the initial damage:

Glutamate excitotoxicity — massive calcium influx via NMDA receptors and AMPA receptors following the depolarisation surge, activating proteases, lipases, and generating reactive oxygen species (ROS). Mitochondrial dysfunction — calcium overload collapses the mitochondrial membrane potential, uncoupling oxidative phosphorylation and triggering cytochrome c release and apoptosis initiation. Cerebral oedema — vasogenic (blood-brain barrier disruption allowing plasma protein extravasation) and cytotoxic (intracellular water accumulation from failed Na+/K+-ATPase function) oedema elevate intracranial pressure. Neuroinflammation — microglial activation, astrocyte reactivity, and peripheral immune cell infiltration (neutrophils within hours, macrophages/monocytes within days) drive inflammatory cytokine production that paradoxically both attempts repair and amplifies secondary neuronal death.

It is in the secondary injury phase that pharmacological research targets exist, and where semax’s mechanisms are most relevant.

Semax Mechanisms in TBI-Relevant Biology

BDNF Upregulation

Brain-derived neurotrophic factor (BDNF) is the most abundant and widely studied neurotrophin in the CNS. It signals through TrkB receptors to promote neuronal survival, dendritic arborisation, synaptic plasticity, and neurogenesis. BDNF is acutely downregulated following TBI due to excitotoxicity-induced neuronal stress and the inflammatory microenvironment — a reduction that contributes to post-TBI neuronal vulnerability and impaired recovery.

Semax’s most consistently documented molecular effect is upregulation of BDNF mRNA expression in hippocampal and cortical neurons. Research has shown semax-induced BDNF elevation in rat hippocampus within hours of administration — an effect mediated at least partly through melanocortin receptor (MCR) signalling upstream of the CREB transcription factor that drives BDNF gene expression. In TBI research models, semax’s capacity to maintain or restore BDNF levels in the peri-lesional region is mechanistically significant: higher BDNF availability promotes survival of neurons at risk in the penumbral zone and supports the axonal sprouting that contributes to functional recovery.

Neuroinflammation Modulation

Post-TBI neuroinflammation is a double-edged sword — initial microglial activation serves to clear debris and produce neurotrophic factors, but sustained or excessive microglial pro-inflammatory polarisation (M1-like phenotype) drives secondary neuronal death via TNF-α, IL-1β, IL-6, and nitric oxide production. Research has identified semax as a modulator of microglial phenotype and inflammatory gene expression following CNS injury.

In ischaemia and TBI models, semax treatment has been associated with reduced pro-inflammatory cytokine expression in peri-lesional tissue and attenuated microglial activation markers — measured by immunohistochemistry (Iba-1 staining) and cytokine mRNA quantification (qRT-PCR). The mechanism is hypothesised to involve semax’s MCR-dependent effects on NF-κB signalling — melanocortin receptor activation through cAMP/PKA pathways can inhibit NF-κB nuclear translocation, reducing transcription of pro-inflammatory target genes.

Semax has also been shown to influence the transition of microglia from pro-inflammatory to anti-inflammatory/reparative phenotypes — accelerating the resolution phase of neuroinflammation that is associated with transition from injury amplification to repair. This phenotypic shift may involve upregulation of anti-inflammatory mediators including IL-10 and TGF-β1 in peri-lesional glia.

Cerebral Blood Flow and Vascular Neuroprotection

Cerebral hypoperfusion — both global (due to post-TBI hypotension and elevated intracranial pressure) and regional (due to focal vasospasm and microvascular plugging by activated platelets and neutrophils) — extends the ischaemic component of secondary TBI and expands the zone of infarction. Semax has been studied in cerebrovascular contexts — particularly ischaemic stroke research — and its effects on cerebral blood flow regulation and vascular preservation are relevant to TBI research.

Research in focal cerebral ischaemia models has documented semax-associated reductions in infarct volume at 24 hours — consistent with vascular or metabolic neuroprotection in the ischaemic penumbra. The mechanism may involve semax-mediated VEGF upregulation (supporting vascular integrity and angiogenesis) and NO-mediated vasodilation that maintains perfusion to at-risk regions. In TBI contexts where focal contusion produces surrounding ischaemic penumbra, analogous mechanisms may be relevant.

Axonal Regeneration Support

Diffuse axonal injury (DAI) — the shearing of axons across white matter tracts at the moment of impact — is the pathological hallmark of moderate-to-severe TBI and the primary substrate of post-TBI cognitive and motor deficits. Axonal regeneration following DAI requires both intrinsic neuronal growth programmes (activation of growth-associated protein-43, GAP-43, and mTOR-dependent protein synthesis) and permissive extracellular matrix conditions.

BDNF — elevated by semax — is a key activator of the intrinsic axonal regeneration programme through TrkB/Akt/mTOR signalling. Research in spinal cord injury models (a related axonal injury model) has documented enhanced axonal sprouting in BDNF-treated animals compared to controls. Whether semax’s BDNF-upregulating effects translate to improved axonal regeneration in TBI-specific white matter injury models is an area of active research interest.

Russian Clinical Research: Context and Limitations

Semax has been approved in Russia and some CIS countries as a neuroprotective drug for ischaemic stroke and brain injury since the 1990s. Russian clinical literature documents its use in stroke, TBI, and encephalopathy research contexts, with generally positive reports on neurological outcome scores and recovery timelines. However, this clinical evidence base requires careful evaluation by Western researchers:

Many Russian semax studies were conducted before the adoption of current rigorous trial design standards (CONSORT guidelines, pre-registration, blinded outcome assessment). Sample sizes are frequently small and control group selection may be suboptimal. Outcome measures used in Russian literature (Barthel index, neurological deficit scales) may differ from endpoints used in contemporary Western TBI research (GOS-E, GOSE, KPSS, neuropsychological batteries). Reporting bias toward positive results is a recognised issue in the Russian clinical literature for neuroprotective compounds.

These limitations do not invalidate the Russian clinical data but require it to be interpreted as hypothesis-generating rather than confirmatory for Western research contexts. Well-designed preclinical mechanistic research and ultimately rigorously designed clinical trials are needed to establish semax’s efficacy profile by current evidential standards.

TBI Research Model Design Considerations

TBI model selection: Controlled cortical impact (CCI) reproduces focal cortical contusion with precisely controllable injury severity. Fluid percussion injury (FPI) produces more diffuse injury with both focal and diffuse components. Weight drop models vary in reproducibility. For semax research, the CCI model is preferred for mechanistic endpoint studies due to its reproducibility and the defined peri-lesional penumbral zone where BDNF and neuroinflammation endpoints are most relevant.

Administration timing: The secondary injury cascade begins within minutes of primary injury. Research protocols examining semax’s neuroprotective potential should include early administration arms (30–60 minutes post-injury) and compare with delayed administration (6 hours, 24 hours) to define the therapeutic window. Semax’s nasal formulation (intranasal administration) is particularly relevant to TBI research given that it provides CNS delivery without the delays of IV access establishment.

Outcome endpoint battery: A comprehensive TBI research protocol should include infarct volume (MRI at 7 days), neurological severity score (beam walk, rotarod, Morris water maze), histopathological markers (neuronal survival by NeuN staining, microglial activation by Iba-1, astrogliosis by GFAP), molecular endpoints (BDNF protein by ELISA, cytokine mRNA by qRT-PCR), and axonal integrity markers (neurofilament by immunostaining, DTI by MRI in larger animal models).

Summary for Researchers

Semax’s mechanisms — BDNF upregulation, neuroinflammation modulation, cerebrovascular neuroprotection, and axonal regeneration support — map directly onto multiple components of the secondary TBI injury cascade. Its intranasal formulation provides CNS delivery through olfactory and trigeminal pathways that is particularly practical in the acute TBI research context. The Russian clinical evidence base, while requiring interpretation with appropriate methodological caveats, provides preliminary human data suggesting neurological outcome benefits that align with the preclinical mechanistic profile.

For TBI researchers, semax offers a well-characterised mechanistic research tool addressing multiple secondary injury pathways simultaneously — a pharmacological profile that is mechanistically more appropriate to TBI’s multicausal secondary injury cascade than single-target neuroprotective approaches that have failed in translation. Rigorous controlled preclinical studies using standardised TBI models and comprehensive outcome batteries are the appropriate next step for establishing semax’s evidence base in this indication.